Epigenomics of pancreatic cancer: A critical role for epigenome-wide studies

Rahul R. Singh, Katie M. Reindl, Rick J. Jansen

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Several challenges present themselves when discussing current approaches to the prevention or treatment of pancreatic cancer. Up to 45% of the risk of pancreatic cancer is attributed to unknown causes, making effective prevention programs difficult to design. The most common type of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC), is generally diagnosed at a late stage, leading to a poor prognosis and 5-year survival estimate. PDAC tumors are heterogeneous, leading to many identified cell subtypes within one patient’s primary tumor. This explains why there is a high frequency of tumors that are resistant to standard treatments, leading to high relapse rates. This review will discuss how epigenetic technologies and epigenome-wide association studies have been used to address some of these challenges and the future promises these approaches hold.

Original languageEnglish (US)
Article number5
Issue number1
StatePublished - Mar 2019


  • DNA
  • Epigenetics
  • Epigenomes
  • Expression
  • Histones
  • Methylation
  • Pancreatic cancer
  • RNA

ASJC Scopus subject areas

  • Genetics
  • Biochemistry, Genetics and Molecular Biology (miscellaneous)
  • Biochemistry
  • Health, Toxicology and Mutagenesis


Dive into the research topics of 'Epigenomics of pancreatic cancer: A critical role for epigenome-wide studies'. Together they form a unique fingerprint.

Cite this